Compare VTEX & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTEX | LXRX |
|---|---|---|
| Founded | 1999 | 1995 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 561.5M | 547.4M |
| IPO Year | 2019 | 2000 |
| Metric | VTEX | LXRX |
|---|---|---|
| Price | $3.94 | $1.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | ★ $6.16 | $4.63 |
| AVG Volume (30 Days) | 1.0M | ★ 2.3M |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $12.64 | N/A |
| Revenue Next Year | $10.57 | $22.16 |
| P/E Ratio | $43.33 | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $2.84 | $0.32 |
| 52 Week High | $6.82 | $1.83 |
| Indicator | VTEX | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 74.10 | 66.31 |
| Support Level | $3.92 | $1.08 |
| Resistance Level | $4.23 | $1.83 |
| Average True Range (ATR) | 0.16 | 0.12 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 97.70 | 84.83 |
Vtex provides a software-as-a-service digital commerce platform for enterprise brands and retailers. Its platform enables customers to execute their commerce plan, including building online stores, integrating and managing orders across channels, and creating marketplaces to sell products from third-party vendors. It generates maximum revenues from Brazil followed by Latin America and the rest of the world.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.